Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Shares Outstanding (Diluted Average) (2016 - 2025)

Guided Therapeutics' Shares Outstanding (Diluted Average) history spans 11 years, with the latest figure at $81.7 million for Q3 2025.

  • For Q3 2025, Shares Outstanding (Diluted Average) rose 43.22% year-over-year to $81.7 million; the TTM value through Sep 2025 reached $81.7 million, up 43.22%, while the annual FY2024 figure was $57.3 million, 12.14% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q3 2025 was $81.7 million at Guided Therapeutics, up from $73.6 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $81.7 million in Q3 2025 and bottomed at $49297.0 in Q1 2023.
  • The 5-year median for Shares Outstanding (Diluted Average) is $51.0 million (2023), against an average of $40.1 million.
  • The largest annual shift saw Shares Outstanding (Diluted Average) crashed 99.76% in 2023 before it skyrocketed 110961.53% in 2024.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $13.4 million in 2021, then skyrocketed by 142.99% to $32.5 million in 2022, then skyrocketed by 57.3% to $51.1 million in 2023, then grew by 12.14% to $57.3 million in 2024, then surged by 42.47% to $81.7 million in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Shares Outstanding (Diluted Average) are $81.7 million (Q3 2025), $73.6 million (Q2 2025), and $68.3 million (Q1 2025).